{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:37:40Z","timestamp":1790149060800,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T00:00:00Z","timestamp":1515801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Committee of Science and Technology, China","award":["12DZ2260100"],"award-info":[{"award-number":["12DZ2260100"]}]},{"name":"the Key Clinical Program of the Ministry of Health","award":["SHDC12010116"],"award-info":[{"award-number":["SHDC12010116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10549-018-4660-y","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T02:23:58Z","timestamp":1515810238000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival"],"prefix":"10.1007","volume":"168","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1752-026X","authenticated-orcid":false,"given":"Guangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,13]]},"reference":[{"key":"4660_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","volume":"36","author":"CK Anders","year":"2009","unstructured":"Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36:237\u2013249","journal-title":"Semin Oncol"},{"key":"4660_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/0284186X.2010.533190","volume":"50","author":"M Ewertz","year":"2011","unstructured":"Ewertz M, Jensen AB (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50:187\u2013193","journal-title":"Acta Oncol"},{"issue":"473\u2013478","key":"4660_CR3","first-page":"481","volume":"29","author":"S Jain","year":"2015","unstructured":"Jain S, Santa-Maria CA, Gradishar WJ (2015) The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncology (Williston Park) 29(473\u2013478):481","journal-title":"Oncology (Williston Park)"},{"key":"4660_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HC Moore","year":"2015","unstructured":"Moore HC, Unger JM, Phillips KA et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923\u2013932","journal-title":"N Engl J Med"},{"key":"4660_CR5","first-page":"269","volume":"306","author":"ML Del","year":"2011","unstructured":"Del ML, Boni L, Michelotti A et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269\u2013276","journal-title":"JAMA"},{"key":"4660_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/annonc\/mdv335.01","volume":"26","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Ceppi M, Poggio F et al (2015) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26:2408\u20132419","journal-title":"Ann Oncol"},{"key":"4660_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-015-0545-7","volume":"14","author":"M Lambertini","year":"2016","unstructured":"Lambertini M, Del ML, Pescio MC et al (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14:1","journal-title":"BMC Med"},{"key":"4660_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436\u2013446","journal-title":"N Engl J Med"},{"key":"4660_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107\u2013118","journal-title":"N Engl J Med"},{"key":"4660_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045\u20131051","journal-title":"J Clin Oncol"},{"key":"4660_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1933719114549856","volume":"22","author":"A Iwase","year":"2015","unstructured":"Iwase A, Nakamura T, Nakahara T et al (2015) Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci 22:519\u2013526","journal-title":"Reprod Sci"},{"key":"4660_CR12","doi-asserted-by":"publisher","first-page":"26627","DOI":"10.1038\/srep26627","volume":"6","author":"L Qiu","year":"2016","unstructured":"Qiu L, Fu F, Huang M et al (2016) Evaluating the survival benefit following ovarian function suppression in premenopausal patients with hormone receptor positive early breast cancer. Sci Rep 6:26627","journal-title":"Sci Rep"},{"key":"4660_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436\u2013446","journal-title":"N Engl J Med"},{"key":"4660_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12032-013-0667-8","volume":"30","author":"G Song","year":"2013","unstructured":"Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30:667","journal-title":"Med Oncol"},{"key":"4660_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10549-009-0313-5","volume":"117","author":"A Sverrisdottir","year":"2009","unstructured":"Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561\u2013567","journal-title":"Breast Cancer Res Treat"},{"key":"4660_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS10-P5-13-07","author":"R Leonard","year":"2010","unstructured":"Leonard R, Adamson D, Anderson R et al (2010) Hormone levels in the option trial show no ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer\u2014an anglo-celtic collaborative group and NCRN trial. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.SABCS10-P5-13-07","journal-title":"Cancer Res"},{"key":"4660_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1200\/JCO.2011.34.6890","volume":"30","author":"PN Munster","year":"2012","unstructured":"Munster PN, Moore AP, Ismail-Khan R et al (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533\u2013538","journal-title":"J Clin Oncol"},{"key":"4660_CR18","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","volume":"29","author":"B Gerber","year":"2011","unstructured":"Gerber B, von Minckwitz G, Stehle H et al (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334\u20132341","journal-title":"J Clin Oncol"},{"key":"4660_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS14-P1-12-02","author":"J Li","year":"2015","unstructured":"Li J, Liu G, Yu K et al (2015) Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: the primary analysis of a randomized controlled phase III trial. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS14-P1-12-02","journal-title":"Cancer Res"},{"key":"4660_CR20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong JH, Geyer CJ et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053\u20132065","journal-title":"N Engl J Med"},{"key":"4660_CR21","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1001\/jama.2015.17291","volume":"314","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Boni L, Michelotti A et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:2632\u20132640","journal-title":"JAMA"},{"key":"4660_CR22","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1093\/annonc\/mdx285","volume":"28","author":"MM Regan","year":"2017","unstructured":"Regan MM, Walley BA, Francis PA et al (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225\u20132232","journal-title":"Ann Oncol"},{"key":"4660_CR23","doi-asserted-by":"crossref","unstructured":"Lambertini M MHLR (2017) Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. In: San Antonio breast cancer symposium 2017, San Anotonio, The United States","DOI":"10.1158\/1538-7445.SABCS17-GS4-01"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4660-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T05:49:09Z","timestamp":1570600149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4660-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,13]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4660"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4660-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,13]]},"assertion":[{"value":"13 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This trial was approved by the review boards in Fudan University Shanghai Cancer Center (No. 090875-3). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}